Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 5/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL123127 | 0.97 | ALDH1A1 (0.47) | ALDH1A1ALOX15MAOAMAPTKDM4E | |
| SCHEMBL9336430 | 0.97 | ALDH1A1 (0.47) | ALDH1A1ALOX15MAOAMAPTKDM4E | |
| Bromide SCHEMBL6744490 | 0.94 | ALDH1A1 (0.45) | ALDH1A1ALOX15MAOAMAPTKDM4E | |
| SCHEMBL9413781 | 0.94 | ALDH1A1 (0.45) | ALDH1A1ALOX15MAOAMAPTKDM4E | |
| Iodide SCHEMBL16764629 | 0.94 | ALDH1A1 (0.45) | ALDH1A1ALOX15MAOAMAPTKDM4E | |
| Iodide SCHEMBL2127044 | 0.94 | ALDH1A1 (0.45) | ALDH1A1ALOX15MAOAMAPTKDM4E | |
| Bromide SCHEMBL7687601 | 0.94 | ALDH1A1 (0.45) | ALDH1A1ALOX15MAOAMAPTKDM4E | |
| Water SCHEMBL4753900 | 0.94 | ALDH1A1 (0.45) | ALDH1A1ALOX15MAOAMAPTKDM4E | |
| Hydrochloric Acid SCHEMBL3316045 | 0.94 | ALDH1A1 (0.45) | ALDH1A1ALOX15MAOAMAPTKDM4E | |
| Hydrochloric Acid SCHEMBL2838012 | 0.94 | ALDH1A1 (0.45) | ALDH1A1ALOX15MAOAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093406-B2 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2012-01-10 | — | — | US | disclosed |
| EP-2190833-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | Novartis Ag (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| WO-2009024615-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BRIARD EMMANUELLE | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BACE2, BACE1, APP | ALDH1A1 2720/4885ALOX15 1806/4885MAOA 618/4885 |
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | BACE2, BACE1, APP | ALDH1A1 2566/4885ALOX15 2619/4885MAOA 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.